Message #21 From:
NewsBot Date: January 16, 2007 01:10:00 PM
AVNR News AVANIR Pharmaceuticals Invites Investors to Its First Quarter Conference Call on Friday, February 9, 2007
ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) will webcast its quarterly
conference call on Friday, February 9, 2007, at 8:00 a.m. Pacific/11:00
a.m. Eastern. The call will be webcast live through AVANIR's corporate
website at www.avanir.com and will
feature Eric Brandt, President and Chief Executive Officer, and Michael
Puntoriero, Senior Vice President and Chief Financial Officer. A press
release announcing the first quarter 2007 financial results will be
released prior to the conference call the same day.
It is recommended that you go to AVANIR's website at least 10 minutes in
advance of the webcast to download any applicable software. For those
who cannot listen to the live broadcast, the online replay will be
available for 30 days, and a phone replay will be available through
February 14, 2007, by dialing 800-642-1687 (domestic) and 706-645-9291
(international) and entering the passcode 6368181.
About AVANIR
AVANIR Pharmaceuticals is focused on developing, acquiring and
commercializing novel therapeutic products for the treatment of chronic
diseases. AVANIR’s products and product
candidates address therapeutic markets that include the central nervous
system, cardiovascular disorders, inflammation and infectious diseases.
AVANIR currently markets FazaClo®,
the only orally-disintegrating formulation of clozapine for the
management of severely ill schizophrenic patients who fail to respond
adequately to standard schizophrenic drug treatments. FazaClo is also
indicated for reducing the risk of suicidal behavior in patients with
schizophrenic or schizoaffective disorder. For full prescribing
information and important safety information regarding FazaClo, please
visit www.fazaclo.com. Zenvia™,
AVANIR's lead product candidate for the treatment of involuntary
emotional expression disorder (IEED), is the subject of an approvable
letter from the FDA and future development plans for this product
candidate are under consideration. The Company does not know at this
time what impact, if any, the ongoing discussions with the FDA for IEED
may have on the development of Zenvia for other indications.
Additionally, AVANIR has completed the patient recruitment in a Phase
III clinical trial with Zenvia as a potential treatment for patients
with painful diabetic neuropathy. AVANIR has active collaborations with
two international pharmaceutical companies: Novartis International
Pharmaceutical Ltd. for the treatment of inflammatory disease and
AstraZeneca for the treatment of cardiovascular disease. The Company's
first commercialized product, abreva®,
is marketed in North America by GlaxoSmithKline Consumer Healthcare and
is the leading over-the-counter product for the treatment of cold sores.
Further information about AVANIR can be found at www.avanir.com.
